Navigation Links
Kuros Completes Patient Recruitment in its European Clinical Study With KUR-023, its Novel Dural Sealant Product Candidate
Date:8/16/2011

ZURICH, August 17, 2011 /PRNewswire/ --

Kuros Biosurgery AG, a biotechnology company focused on the development of novel biomaterials and bioactive-biomaterial combination products for trauma, wound and spinal indications, announced today that it has completed patient recruitment in a clinical trial investigating the safety and efficacy of KUR-023, its novel dural sealant product candidate. Kuros intends that this trial will support CE Marking of KUR023.

KUR-023 is a synthetic hydrogel-based sealant that utilises Kuros' synthetic technology.  The product candidate is administered as a spray with the aim of ensuring water-tight closure of incisions or tearsthrough the dura mater.  It is intended to be used as an adjunct to normal closure techniques such as suturing.

The trial is a European, single arm, multi-center study in which 41 patients have been treated. The primary endpoint refers to the prevention of intraoperative leakage with secondary endpoints related to safety and further effectiveness assessment.

KUR-023 is delivered from a double barrelled syringe with a mixing spray tip. The product candidate is delivered as a spray which then arrives on the dura as a liquid, conforms to the surface, and quickly polymerises.  The applied gel is expected to adhere strongly to the dural surface and be able to withstand cerebral pressures in excess of those experienced in a patient.  The gel is designed to be easy to apply, to swell minimally (addresses a common problem with hydrogels), to dissolve over a period of a few months and not to interfere with the natural healing process.

Kuros' synthetic technology is based on technology originally developed by Prof. Jeffrey Hubbell. The technology uses a cross-linking chemistry which is highly specific, does not generate any heat and is an addition reaction, meaning that no chemicals are released during the polymerisation process.

Didier Cowling, Chief Executive
'/>"/>

SOURCE Kuros Biosurgery AG
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Kuros Announces Allowance of US Patent for the Local Application of Parathyroid Hormone (PTH) for Bone Healing
2. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
5. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
6. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
7. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
8. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
9. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
10. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
11. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 11, 2014 According to ... Composition of Material, Application (Healthcare, Homeland security, Industrial ... (Personal Instrument, Hand-Held Instruments, Fixed, and Installed Instruments) ... 2013 - 2020", published by MarketsandMarkets, the Scintillator Market is ... from 2014 to 2020, and reach $479.16 Million ...
(Date:7/11/2014)... 11, 2014  Australian drug delivery company, Phosphagenics Limited ... raised A$19.3 million via a placement of A$16.3 million ... the U.S., Asia and ... share purchase plan (SPP) to be offered to existing ... in two tranches. "This capital raising positions ...
(Date:7/11/2014)... 2014 Research and Markets ( http://www.researchandmarkets.com/research/tjlw9k/immunoprotein ... "Immunoprotein Diagnostic Testing Market - Forecasts to 2019: ... 6% and is expected to be valued at ... http://photos.prnewswire.com/prnh/20130307/600769 ... been segmented according to immunoprotein types which include ...
Breaking Medicine Technology:Scintillator Market will be worth $479.16 Million by 2020 2Scintillator Market will be worth $479.16 Million by 2020 3Scintillator Market will be worth $479.16 Million by 2020 4Phosphagenics' A$19.3 million Capital Raising 2Phosphagenics' A$19.3 million Capital Raising 3Immunoprotein Diagnostic Testing Market - Forecasts to 2019: Expected to grow at the highest CAGR of 6% and is expected to be valued at USD 4,943.0 million 2
... Nov. 1, 2010 The National Quality Forum ... of its eight member councils.   ... to improving the quality of American healthcare by ... endorsing national consensus standards for measuring and publicly ...
... Octapharma AG , one of ... and Octapharma USA today announced that patients ... a multi-center study that is researching the use of ... human cell line (Human-cl rhFVIII). Researchers are investigating Human-cl ...
Cached Medicine Technology:National Quality Forum Members Elect New Council Leaders 2Octapharma Clinical Trial Begins in the U.S. and Germany Treating Hemophilia A Patients with First Recombinant Factor VIII Derived from a Human Cell-Line 2Octapharma Clinical Trial Begins in the U.S. and Germany Treating Hemophilia A Patients with First Recombinant Factor VIII Derived from a Human Cell-Line 3
(Date:7/13/2014)... Ticket Down is a reliable source ... For the fifth straight year (and second under the current ... American stadiums this summer. The tournament features eight club teams ... teams are split into two groups of four and upon ... will compete to become champion. One team that has had ...
(Date:7/13/2014)... Nature Genetics identifies a novel genetic ... eosinophillic esophagitis (EoE), opening up potential new therapeutic ... , EoE is a chronic inflammatory disorder ... allergic hypersensitivity to certain foods and an over-accumulation ... eosinophils (part of the body,s immune system). EoE ...
(Date:7/13/2014)... Recently, MillionaireCasket.com, a well-known casket manufacturer from ... . Additionally, the company’s chief executive officer has announced a ... caskets are offered at discounted prices, from 15 to 26 ... caskets are in huge demand in the current market. We ... We have a lot of high quality products for sale. ...
(Date:7/13/2014)... Micro irrigation systems are mainly utilized ... as wells as to maintain soil quality. The application ... become a dominant revenue generator for manufacturers in future. ... resource costs has led to the adoption of micro ... further caused massive demand for micro irrigation systems, as ...
(Date:7/13/2014)... (PRWEB) July 13, 2014 Fuel additives ... as gasoline, diesel, jet fuel, kerosene, and so on, ... also responsible for reducing the corrosion effects caused by ... when added to any fuel, provide economies of scale ... these escalate the overall cost of the fuel products. ...
Breaking Medicine News(10 mins):Health News:AS Roma vs Real Madrid Tickets in Dallas at Cotton Bowl: Ticket Down Slashes Ticket Prices for Real Madrid vs AS Roma Guinness International Champions Cup Match 2Health News:AS Roma vs Real Madrid Tickets in Dallas at Cotton Bowl: Ticket Down Slashes Ticket Prices for Real Madrid vs AS Roma Guinness International Champions Cup Match 3Health News:Study finds cause of mysterious food allergy, suggests new treatment strategy 2Health News:Study finds cause of mysterious food allergy, suggests new treatment strategy 3Health News:Cheap Oak Caskets Recently Unveiled By China Casket Manufacturer MillionaireCasket.com 2Health News:Agricultural Micro Irrigation System Market is Expected to Grow at a CAGR of 18.1%, from 2013 to 2018 - New Report by MicroMarket Monitor 2Health News:Agricultural Micro Irrigation System Market is Expected to Grow at a CAGR of 18.1%, from 2013 to 2018 - New Report by MicroMarket Monitor 3Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 2Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 3Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 4
... The chances of infection are boosted 50-fold to 100,000-fold, study ... discovery that perplexes HIV experts, an international team reports that ... of the virus to do its damage. , According to ... , the fibers capture the virus and then ferry it ...
... this dependence could stop disease before it starts , ... growth factors contributes to the development of cancers caused ... a normally silent gene, scientists say. , The team ... addiction might help prevent cancer growth. , They ...
... eye also detects light for a number of non-visual phenomena. ... sleep/wake cycle, which is synchronized by the effects of light ... a study published online on December 13th in Current Biology, ... to light remain intact, suggesting that visual and non-visual responses ...
... Dec. 13 A letter recently sent to,presidential ... according to groups representing full-service community hospitals.,Those groups, ... Hospital,Association (AHA), sent their own letter to the ... impact of limited-service facilities, which,drive up the nation,s ...
... to common ... antibiotic treatment, BERKELEY SPRINGS, W.Va., ... sprays provide little,to no relief of symptoms associated with sinus infections. ... they,took antibiotics, steroids, or placebos., One such study appears in ...
... Extend Product Offering to Healthcare Customers, DALLAS, ... leading provider of electronic transaction services to the,Healthcare ... an agreement,to acquire substantially all the assets of ... is subject to due diligence and is structured,as ...
Cached Medicine News:Health News:Fibers in Semen Help HIV Penetrate Cells 2Health News:Cell 'Addiction' to Growth Factors May Help Spur Cancers 2Health News:Blind humans lacking rods and cones retain normal responses to non-visual effects of light 2Health News:Blind humans lacking rods and cones retain normal responses to non-visual effects of light 3Health News:Full-Service Community Hospitals Blast Misleading Letter to Candidates From Limited-Service Hospitals 2Health News:Full-Service Community Hospitals Blast Misleading Letter to Candidates From Limited-Service Hospitals 3Health News:Full-Service Community Hospitals Blast Misleading Letter to Candidates From Limited-Service Hospitals 4Health News:Full-Service Community Hospitals Blast Misleading Letter to Candidates From Limited-Service Hospitals 5Health News:31 Million Americans Suffer From Sinus Infections 2Health News:Claimsnet to Acquire Acceptius 2
Used to introduce balloon, diagnostic and guiding catheters, or other devices for intervention....
Used to introduce balloon, electrode, closed or non-tapered end catheters and other devices for intervention....
Used to introduce large balloon, closed and non-tapered end catheters or other devices for intervention....
Used for contralateral access to the iliac artery for interventional procedures after initial wire guide positioning has been established.,NOTE: Use of a heavy-duty wire guide is recommended....
Medicine Products: